questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines du sang
Immunoprotéines
Protéines du système du complément
Enzymes activatrices du complément
Complement C3-C5 Convertases
Complement C3-C5 Convertases : Questions médicales fréquentes
Termes MeSH sélectionnés :
Neoplasm Recurrence, Local
Diagnostic
5
Déficience du complément
Tests de laboratoire
Tests de complément
Hémolyse
Infections
Maladies auto-immunes
Sérum
Activité enzymatique
Symptômes
5
Éruptions cutanées
Douleurs articulaires
Troubles neurologiques
Inflammation cérébrale
Infections bactériennes
Maladies auto-immunes
Déficience du complément
Symptômes cliniques
Prévention
5
Prévention
Diagnostic précoce
Alimentation équilibrée
Nutrition
Suivi médical
Complications
Conseils génétiques
Transmission héréditaire
Traitements
5
Immunoglobulines
Antibiotiques
Médicaments anti-inflammatoires
Inhibiteurs du complément
Transfusions sanguines
Protéines du complément
Thérapie génique
Déficiences génétiques
Médecine personnalisée
Soins individualisés
Complications
5
Infections graves
Maladies auto-immunes
Complications réversibles
Gestion des complications
Qualité de vie
Douleurs chroniques
Complications neurologiques
Troubles cognitifs
Lésions tissulaires
Réactions inflammatoires
Facteurs de risque
5
Antécédents familiaux
Maladies auto-immunes
Infections fréquentes
Déficience du complément
Maladies génétiques
Prédisposition
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Complement C3-C5 Convertases : Questions médicales les plus fréquentes",
"headline": "Complement C3-C5 Convertases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Complement C3-C5 Convertases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-14",
"dateModified": "2025-03-09",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Complement C3-C5 Convertases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Enzymes activatrices du complément",
"url": "https://questionsmedicales.fr/mesh/D003166",
"about": {
"@type": "MedicalCondition",
"name": "Enzymes activatrices du complément",
"code": {
"@type": "MedicalCode",
"code": "D003166",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Alternative pathway C3-C5 Convertases",
"alternateName": "Complement C3-C5 Convertases, Alternative Pathway",
"url": "https://questionsmedicales.fr/mesh/D050578",
"about": {
"@type": "MedicalCondition",
"name": "Alternative pathway C3-C5 Convertases",
"code": {
"@type": "MedicalCode",
"code": "D050578",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.500"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Alternative pathway complement C3 convertase",
"alternateName": "Complement C3 Convertase, Alternative Pathway",
"url": "https://questionsmedicales.fr/mesh/D051561",
"about": {
"@type": "MedicalCondition",
"name": "Alternative pathway complement C3 convertase",
"code": {
"@type": "MedicalCode",
"code": "D051561",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.500.374"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Alternative pathway C5 convertase",
"alternateName": "Complement C5 Convertase, Alternative Pathway",
"url": "https://questionsmedicales.fr/mesh/D051566",
"about": {
"@type": "MedicalCondition",
"name": "Alternative pathway C5 convertase",
"code": {
"@type": "MedicalCode",
"code": "D051566",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.500.750"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Classical pathway C3-C5 Convertases",
"alternateName": "Complement C3-C5 Convertases, Classical Pathway",
"url": "https://questionsmedicales.fr/mesh/D050579",
"about": {
"@type": "MedicalCondition",
"name": "Classical pathway C3-C5 Convertases",
"code": {
"@type": "MedicalCode",
"code": "D050579",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.750"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Classical pathway complement C3 convertase",
"alternateName": "Complement C3 Convertase, Classical Pathway",
"url": "https://questionsmedicales.fr/mesh/D051574",
"about": {
"@type": "MedicalCondition",
"name": "Classical pathway complement C3 convertase",
"code": {
"@type": "MedicalCode",
"code": "D051574",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.750.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Classical pathway C5 convertase",
"alternateName": "Complement C5 Convertase, Classical Pathway",
"url": "https://questionsmedicales.fr/mesh/D051577",
"about": {
"@type": "MedicalCondition",
"name": "Classical pathway C5 convertase",
"code": {
"@type": "MedicalCode",
"code": "D051577",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.750.750"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Mannose-Binding Protein-Associated Serine Proteases",
"alternateName": "Mannose-Binding Protein-Associated Serine Proteases",
"url": "https://questionsmedicales.fr/mesh/D050606",
"about": {
"@type": "MedicalCondition",
"name": "Mannose-Binding Protein-Associated Serine Proteases",
"code": {
"@type": "MedicalCode",
"code": "D050606",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.875"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Complement C3-C5 Convertases",
"alternateName": "Complement C3-C5 Convertases",
"code": {
"@type": "MedicalCode",
"code": "D050577",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "John D Lambris",
"url": "https://questionsmedicales.fr/author/John%20D%20Lambris",
"affiliation": {
"@type": "Organization",
"name": "Department of Laboratory Medicine and Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA."
}
},
{
"@type": "Person",
"name": "Tom Eirik Mollnes",
"url": "https://questionsmedicales.fr/author/Tom%20Eirik%20Mollnes",
"affiliation": {
"@type": "Organization",
"name": "Research Laboratory, Nordland Hospital, 8092 Bodø, Norway."
}
},
{
"@type": "Person",
"name": "Dimitrios C Mastellos",
"url": "https://questionsmedicales.fr/author/Dimitrios%20C%20Mastellos",
"affiliation": {
"@type": "Organization",
"name": "National Center for Scientific Research 'Demokritos', Athens, Greece."
}
},
{
"@type": "Person",
"name": "Giuseppe Remuzzi",
"url": "https://questionsmedicales.fr/author/Giuseppe%20Remuzzi",
"affiliation": {
"@type": "Organization",
"name": "Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy."
}
},
{
"@type": "Person",
"name": "Markus Huber-Lang",
"url": "https://questionsmedicales.fr/author/Markus%20Huber-Lang",
"affiliation": {
"@type": "Organization",
"name": "Institute of Clinical and Experimental Trauma Immunology, University Hospital of Ulm, Ulm, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Classification of Local Recurrence After Nipple-Sparing Mastectomy Based on Location: The Features of Nipple-Areolar Recurrence Differ from Those of Other Local Recurrences.",
"datePublished": "2022-11-13",
"url": "https://questionsmedicales.fr/article/36371582",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1245/s10434-022-12760-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Feasibility of local therapy for recurrent pancreatic cancer.",
"datePublished": "2022-05-24",
"url": "https://questionsmedicales.fr/article/35641368",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.pan.2022.05.004"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ultrasound Assessment of Skin Tumors Local Recurrence.",
"datePublished": "2023-05-17",
"url": "https://questionsmedicales.fr/article/37195073",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jum.16255"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pathological determinants of outcome following resection of locally advanced or locally recurrent rectal cancer.",
"datePublished": "2023-06-26",
"url": "https://questionsmedicales.fr/article/37442715",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejso.2023.06.023"
}
},
{
"@type": "ScholarlyArticle",
"name": "Intraparenchymal metastases as a cause for local recurrence of pancreatic cancer.",
"datePublished": "2022-11-21",
"url": "https://questionsmedicales.fr/article/36371607",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/his.14839"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines du sang",
"item": "https://questionsmedicales.fr/mesh/D001798"
},
{
"@type": "ListItem",
"position": 5,
"name": "Immunoprotéines",
"item": "https://questionsmedicales.fr/mesh/D007162"
},
{
"@type": "ListItem",
"position": 6,
"name": "Protéines du système du complément",
"item": "https://questionsmedicales.fr/mesh/D003165"
},
{
"@type": "ListItem",
"position": 7,
"name": "Enzymes activatrices du complément",
"item": "https://questionsmedicales.fr/mesh/D003166"
},
{
"@type": "ListItem",
"position": 8,
"name": "Complement C3-C5 Convertases",
"item": "https://questionsmedicales.fr/mesh/D050577"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Complement C3-C5 Convertases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Complement C3-C5 Convertases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-04",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Complement C3-C5 Convertases",
"description": "Comment diagnostiquer une déficience en convertases C3-C5 ?\nQuels tests sont utilisés pour évaluer l'activité du complément ?\nQuels signes cliniques suggèrent une activation du complément ?\nPeut-on mesurer l'activité des convertases dans le sang ?\nQuels marqueurs biologiques sont associés aux convertases ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Neoplasm+Recurrence,+Local#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Complement C3-C5 Convertases",
"description": "Quels symptômes indiquent une activation excessive du complément ?\nComment se manifestent les troubles liés aux convertases ?\nLes troubles du complément causent-ils des symptômes neurologiques ?\nQuels signes indiquent une déficience en C3 ?\nLes symptômes varient-ils selon le type de déficience ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Neoplasm+Recurrence,+Local#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Complement C3-C5 Convertases",
"description": "Peut-on prévenir les déficiences en complément ?\nQuelles mesures préventives peuvent réduire les infections ?\nLes patients doivent-ils éviter certains aliments ?\nComment le suivi médical aide-t-il à prévenir les complications ?\nLes conseils génétiques sont-ils utiles pour les familles ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Neoplasm+Recurrence,+Local#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Complement C3-C5 Convertases",
"description": "Quels traitements sont disponibles pour les déficiences en complément ?\nComment traiter une activation excessive du complément ?\nLes transfusions sanguines aident-elles en cas de déficience ?\nY a-t-il des thérapies géniques pour les déficiences en complément ?\nLes traitements sont-ils personnalisés selon le patient ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Neoplasm+Recurrence,+Local#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Complement C3-C5 Convertases",
"description": "Quelles complications peuvent survenir avec une déficience en C3 ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nLes complications neurologiques sont-elles fréquentes ?\nQuelles sont les complications liées à l'activation excessive du complément ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Neoplasm+Recurrence,+Local#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Complement C3-C5 Convertases",
"description": "Quels facteurs augmentent le risque de déficience en complément ?\nL'âge influence-t-il le risque de troubles du complément ?\nLes infections fréquentes sont-elles un facteur de risque ?\nLe sexe joue-t-il un rôle dans les troubles du complément ?\nLes maladies génétiques augmentent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Neoplasm+Recurrence,+Local#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en convertases C3-C5 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins mesurant les niveaux de C3 et C5 peuvent indiquer une déficience."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité du complément ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests d'hémolyse et les dosages de protéines du complément sont courants."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques suggèrent une activation du complément ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des infections récurrentes ou des maladies auto-immunes peuvent indiquer une activation."
}
},
{
"@type": "Question",
"name": "Peut-on mesurer l'activité des convertases dans le sang ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests spécifiques peuvent évaluer l'activité des convertases dans le sérum."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques sont associés aux convertases ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux de C3a et C5a, produits de clivage, sont des marqueurs importants."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une activation excessive du complément ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des éruptions cutanées, des douleurs articulaires et de la fièvre peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment se manifestent les troubles liés aux convertases ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent se manifester par des infections fréquentes et des réactions inflammatoires."
}
},
{
"@type": "Question",
"name": "Les troubles du complément causent-ils des symptômes neurologiques ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles neurologiques peuvent survenir en raison d'une inflammation cérébrale."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une déficience en C3 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des infections bactériennes récurrentes et des maladies auto-immunes peuvent être des signes."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de déficience ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier selon que la déficience concerne C3 ou C5."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les déficiences en complément ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un diagnostic précoce peut aider à gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Quelles mesures préventives peuvent réduire les infections ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des vaccinations et une bonne hygiène peuvent aider à réduire le risque d'infections."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils éviter certains aliments ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'y a pas de restrictions alimentaires spécifiques, mais une alimentation équilibrée est conseillée."
}
},
{
"@type": "Question",
"name": "Comment le suivi médical aide-t-il à prévenir les complications ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier permet d'identifier et de traiter rapidement les complications potentielles."
}
},
{
"@type": "Question",
"name": "Les conseils génétiques sont-ils utiles pour les familles ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les conseils génétiques peuvent aider à comprendre les risques de transmission."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les déficiences en complément ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des immunoglobulines intraveineuses et des antibiotiques prophylactiques."
}
},
{
"@type": "Question",
"name": "Comment traiter une activation excessive du complément ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments anti-inflammatoires et des inhibiteurs du complément peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Les transfusions sanguines aident-elles en cas de déficience ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les transfusions peuvent aider à restaurer les niveaux de protéines du complément."
}
},
{
"@type": "Question",
"name": "Y a-t-il des thérapies géniques pour les déficiences en complément ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours sur les thérapies géniques pour traiter ces déficiences."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés selon le patient ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements sont souvent adaptés en fonction des besoins individuels du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une déficience en C3 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des infections graves, des maladies auto-immunes et des complications rénales peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent réduire la qualité de vie en entraînant des douleurs chroniques et des limitations fonctionnelles."
}
},
{
"@type": "Question",
"name": "Les complications neurologiques sont-elles fréquentes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications neurologiques peuvent survenir, notamment des troubles cognitifs."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications liées à l'activation excessive du complément ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des lésions tissulaires et des réactions inflammatoires peuvent se produire."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de déficience en complément ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents familiaux et certaines maladies auto-immunes augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de troubles du complément ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque peut augmenter avec l'âge en raison de la dégradation du système immunitaire."
}
},
{
"@type": "Question",
"name": "Les infections fréquentes sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des infections fréquentes peuvent indiquer une déficience sous-jacente du complément."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans les troubles du complément ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines déficiences sont plus fréquentes chez les femmes en raison de facteurs hormonaux."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques augmentent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies génétiques peuvent prédisposer à des déficiences du complément."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
7 publications dans cette catégorie
Affiliations :
5 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
5 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
5 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
4 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
4 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
3 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
3 publications dans cette catégorie
Publications dans "Complement C3-C5 Convertases" :
3 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
Little information is available about the clinical and pathologic characteristics of local recurrence (LR) after nipple-sparing mastectomy according to the locations of LR....
This study classified 99 patients into the following two groups according to the location of LR after nipple-sparing mastectomy: nipple-areolar recurrence (NAR) group and other locations of LR (oLR) g...
For about half of the patients (44.4 %) with NAR, the primary cancer was estrogen receptor (ER)-negative and human epidermal growth factor receptor 2 (HER2)-positive. Conversely, in most of the patien...
This multi-institutional retrospective study demonstrated that the features of NAR, such as the characteristics of the primary and recurrent tumors and the prognostic factors after LR resection, were ...
Despite advances in perioperative management, recurrence after curative pancreatectomy is a critical issue in the treatment of pancreatic ductal adenocarcinoma (PDAC). The significance of local therap...
We reviewed the medical records of patients with PDAC who underwent curative resection at our institution between January 2009 and December 2019. We examined the patterns of relapse and assessed the c...
A total of 246 patients with PDAC who underwent R0 or R1 resection were included in this study. The 3-year overall survival (OS) rate was 39.8%, and the 1-year recurrence-free survival rate was 51.2% ...
Our results suggest that a multimodal approach may improve the clinical outcomes of patients with recurrent PDAC....
Skin cancer may recur at or around the surgical site despite wide excisions. Prompt clinical and sonographic detection of local recurrence is important since subjects with relapsing melanomas or nonme...
Pathological factors that influence and predict survival following pelvic exenteration (PE) for locally advanced (LARC) or locally recurrent rectal cancer (LRRC), especially LRRC, remain poorly unders...
A retrospective cohort study was performed for all patients undergoing a curative PE for LARC or LRRC between 2008 and 2021 at a tertiary referral UK specialist colorectal hospital. Cox regression ana...
388 patients were included in the analysis with 256 resections for LARC and 132 for LRRC. 62.4% of patients were male with a median age of 59 years (IQR 49-67). 247 (64%) partial pelvic exenterations ...
A positive resection margin and poorly differentiated tumours are significant negative prognostic markers for survival and recurrence in LARC. The results of this study support the need to look for al...
Using CODA, a technique for three-dimensional reconstruction of large tissues, Kiemen et al. report observation of a microscopic focus of pancreatic cancer found in the vasculature of grossly normal h...
The initial approach to the treatment of desmoid tumors has changed from surgical resection to watchful waiting. However, surgery is still sometimes considered for some patients, and it is likely that...
We sought to explore whether a combined molecular and clinical prognostic model for relapse in patients with desmoid tumors treated with surgery would allow us to identify patients who might do well w...
This was a retrospective, single-center study of 107 patients with desmoid tumors who were surgically treated between January 1980 and December 2015, with a median follow-up of 106 months (range 7 to ...
The multivariable analysis showed that S45F mutations (hazard ratio 5.25 [95% confidence interval 2.27 to 12.15]; p < 0.001) and tumor in the extremities (HR 3.15 [95% CI 1.35 to 7.33]; p = 0.008) wer...
CTNNB1 S45F mutations combined with other clinical variables are a potential prognostic biomarker associated with the risk of relapse in patients with desmoid tumors. The developed nomogram is simple ...
Level III, therapeutic study....
A first local recurrence is common after resection or radiotherapy for brain metastasis (BM). However, patients with BMs can develop multiple local recurrences over time. Published data on second loca...
Patients were identified from a database at Brigham and Women's Hospital in Boston. Hazard ratios and 95% confidence intervals for predictors of a second local recurrence were computed using a Cox pro...
Of 170 identified surgically treated first locally recurrent lesions, 74 (43.5%) progressed to second locally recurrent lesions at a median of 7 months after craniotomy. Subtotal resection of the firs...
A second local recurrence occurred after 43.5% of craniotomies for first recurrent lesions. Subtotal resection and infratentorial location were the strongest risk factors for worse second local recurr...
The current study was undertaken to provide more detailed prognostic models for early prediction of local recurrences and local recurrence free survival (RFS) using different radiologic and pathologic...
One hundred patients with locally advanced rectal carcinomas decided to receive neoadjuvant CRT were retrospectively recruited, Hazard ratios (HR) were determined in the two cox regression models and ...
HR of 1st group of models: T+N, T+N+G, T+N+G+S, T+N+G+S+PNI, and T+N+G+S+PNI+R were summated and categorized into scores, these scores were significantly correlated with the risk of recurrence (Somer'...
We propose that the addition of biologic factors to staging of rectal cancer provide precise stratification and association with local recurrences in patients received preoperative CRT....
This study aims to identify prognostic factors and define the best extent of surgery for optimizing treatment of local recurrence (LR) following colorectal cancer (CRC)....
An institutional database of consecutive patients who underwent radical resection (R0/R1) of LR following CRC was analyzed prospectively from 2010 to 2021 at one tertiary cancer center....
In this study, 75 patients were included with LR following CRC and analyzed. Patients were categorized as compartmental resections (CompRe) (n = 47) if all adjacent organs were systematically removed,...
Complete compartmental surgery is safe and improves local control. Optimal LR resection needs to remove all contiguous organs, with or without tumor involvement....
RET-fused mesenchymal neoplasms mostly affect the soft tissue of paediatric patients. Given their responsiveness to selective RET inhibitors, it remains critical to identify those extraordinary cases ...
Clinicopathological features were assessed and partner agnostic targeted next-generation sequencing on clinically validated platforms were performed. The patients were 18, 53, and 55 years old and inc...
Our study expands the clinicopathological and genetic spectrum of mesenchymal neoplasms associated with RET fusions....
